Walbert Timothy P 4

What Happened

• Timothy P. Walbert, a director of Mirum Pharmaceuticals (MIRM), was granted two equity awards on 2026-06-15: a 3,772-share derivative award and 1,980 restricted stock units (RSUs), a total of 5,752 contingent units. Both awards show a grant price of $0.00 and are reported as derivative awards (no cash paid).
• These are grants/awards (code A), not purchases or sales — common as part of director compensation. There were no immediate sales or cash proceeds reported.

Key Details

• Transaction date: 2026-06-15; Form 4 filed: 2026-06-17 (appears timely).
• Awards: 3,772-share derivative award (footnote F1) and 1,980 RSUs (footnote F2); combined = 5,752 units. Grant price reported as $0.00.
• Shares owned after transaction: not disclosed in the provided summary.
• Vesting/footnotes:
  • F1: The 3,772-share award vests on the first anniversary of the grant date, and in any case will be fully vested by the Issuer's 2027 annual stockholder meeting.
  • F2: Each of the 1,980 restricted stock units represents a contingent right to receive one share and vests on the first anniversary of the grant date, and will be fully vested by the Issuer's 2027 annual stockholder meeting.
• No 10b5-1 plan, tax-withholding sale, or immediate sale reported.

Context

• These are derivative/RSU awards that convert into common shares only upon vesting; they do not reflect an open-market purchase or sale and do not by themselves indicate the insider is buying or selling stock.
• Grants to directors are routine compensation. For retail investors, purchases are often more informative about personal conviction; this filing documents compensation-related awards with scheduled vesting.